Two firms are warned by FDA
Executive Summary
China’s Henan Lihua Pharmaceutical and France’s Biologique Recherche have each been hit with warning letters from the US Food and Drug Administration (FDA) regarding their manufacturing facilities. Inspections at the sites unearthed “significant deviations” from current good manufacturing practice (cGMP).